3mg Semaglutide Pills and What They're Actually Used For

Step 1: Understand which semaglutide product you're looking at

Semaglutide exists in tablet form under two brand names in the UK, and they are not interchangeable. Rybelsus (made by Novo Nordisk) comes in 3mg, 7mg and 14mg tablets and is prescribed to adults with type 2 diabetes to help control blood sugar. It is not licensed for weight loss, and prescribers cannot legally or appropriately use it as one. The 3mg Rybelsus tablet is specifically the starting strength, used for the first month to help the body adjust before escalating to higher diabetes doses.

The Wegovy weight-loss tablet is an entirely separate product. MHRA approval for it arrived on 11 June 2026, making the UK the first country in Europe to authorise an oral GLP-1 medicine specifically for weight management. Its dosing sequence (1.5mg, 4mg, 9mg, 25mg) shares no steps with Rybelsus. The oral semaglutide option for weight loss is built around that schedule alone. If you see a listing, clinic or service offering a 3mg semaglutide pill for slimming, that is a red flag worth taking seriously.

Understanding the difference is not a technical footnote. It affects whether the treatment you receive is the right one, prescribed for the right reason, by a clinician who has assessed your full picture.

Step 2: Know the Wegovy tablet's actual starting point and how it progresses

The Wegovy oral tablet starts at 1.5mg once daily. That first step, like the 3mg opener in Rybelsus, is primarily about tolerability, letting your digestive system adapt to the medicine before the dose climbs. From there, a prescriber steps the dose up through 4mg and 9mg to the 25mg maintenance level, spending at least a month at each stage. The titration pace matters: moving too quickly is one of the main drivers of early side effects, particularly nausea.

How you take it matters just as much as the dose. The tablet is swallowed whole, first thing in the morning, with a small amount of plain water (roughly up to 120ml) on a completely empty stomach. Then you wait at least 30 minutes before eating, drinking anything else (coffee included) or taking other oral medicines. One practical upside over the injection: no refrigeration. You can keep the pack in a bedside drawer or a handbag rather than clearing space in the fridge door. That convenience is meaningful for people who travel frequently or simply find the injection's cold-chain requirements fiddly.

For more on how the oral format compares day-to-day with the injection, the semaglutide tablet overview covers both routes side by side.

Step 3: Check whether the weight-loss tablet might be right for you

The Wegovy oral tablet is licensed for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes. It is used alongside a reduced-calorie diet and increased physical activity, not instead of them. Lower BMI thresholds can apply for certain ethnic backgrounds under UK clinical guidance, so the number on your BMI calculator is not the whole story.

These are prescription-only medicines. No online form or checklist can confirm suitability, that is a clinical decision made by a GPhC-registered prescriber who has reviewed your health history, any medicines you take, and relevant contraindications. People who are pregnant, breastfeeding or actively trying to conceive should not use semaglutide for weight management; the same applies to anyone under 18. A prescriber will also want to know about any history of pancreatitis or certain gastrointestinal conditions before recommending treatment.

The oral semaglutide guide goes into the eligibility picture in more detail if you want to read further before speaking to anyone. Understanding what the treatment costs in private practice is also a practical early step, since NHS access to the Wegovy tablet would require a separate NICE appraisal process that had not begun at launch.

What the trial evidence actually showed

The MHRA approval was underpinned by the OASIS 4 phase 3 trial: 307 adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes, over 64 weeks. Average weight loss across all participants (regardless of how consistently they took the tablets) was around 13.6%, compared with around 2.4% in the placebo group. Among participants who followed the programme fully throughout the trial, average weight loss was closer to 17%. That higher figure is real, but it applies specifically to the fully-adherent group; it is not the overall trial average, and it should not be quoted as if it were.

As the semaglutide pills overview notes, gastrointestinal side effects (nausea, diarrhoea, constipation and related symptoms) were the most commonly reported, affecting the majority of participants on the active treatment. Most were mild to moderate and tended to ease as the body adjusted. You can report any suspected side effects, or flag a concern about a suspect seller, via the MHRA Yellow Card scheme.

If you'd like to discuss whether an oral semaglutide option suits your situation, our prescribers review consultations the same day. That's the right place to start.